Ziccum’s project portfolio

Partner with Ziccum’s project team

We run Feasibility and Evaluation studies as part of a formal collaboration agreement for a wide range of clients: from big pharma development teams and biotech startups to university research departments.

These external development projects are a crucial part of our offering. They aim to develop and license novel thermostable formulations of next-generation vaccines and biomolecules.

Reach out to meet us - and expand the possibilities of your API.

Our Project portfolio overview

The Ziccum pipeline of external projects is depicted in a portfolio overview. This gives a general representation of the key steps towards the desired commercialization by entering into license agreements, licensing the LaminarPace technology for specific applications, and the current status of each project. The actual progress in a specific project may proceed via alternative or additional steps, and the timeline varies greatly depending on the resulting read-outs and the counterpart preferences.

Pharmaceutical development in general is subject to very strict confidentiality, and certain collaborations are given without partner name publication, until name disclosure is possible.

The company also pursues earlier dialogues with other counterparts in on-going business development efforts.

Project portfolio overview as of 31 March, 2023

Want to explore possibilities for your API further? Contact us.

What sets a Ziccum development project apart?

As a unique, ambient methodology, LaminarPace drying delivers new insights into molecules’ properties, stability, thermostability and potential for new administration and processing options.

Expertise

Ziccum’s project team has extensive expertise and experience in pharmaceutical formulation, biochemistry and particle engineering.

Versatility

LaminarPace has formulated mRNA, proteins, peptides, antibodies, lipids and enzymes.as dry powders. The system has worked successfully with a range of excipients, and adjuvants and antigens.

Thermostability

LaminarPaceTM drying offers advanced thermostability outcomes and advanced opportunities for novel administration routes.

Particle engineered

Ambient drying allows greater control over key properties of particles, and its particle-engineered powders are fast-dissolving. Evaluation and Feasibility studies can evaluate a substances’ capacity for inhalation, transdermal or topical application through the skin or reconstitution for intravenous administration.

Our projects can help clients see molecules and compounds they have worked with for years in a new way.

Because it is a new methodology LaminarPace can teach you more about your substance, illuminating new characteristics in stability, thermostability, API activity and particle dissolution.

That's why we always take a big-picture as well as stepwise approach – because we’re aware of the new possibilities that this formulation can deliver.

- Louise Egeblad, Ziccum external project manager

Communication and cooperation

Every Ziccum Feasibility and Applicability study is built on our commitment to providing the best possible outcome to our clients – based on clear communication and dialogue. When you speak, we listen.

This clear dialogue from day one enables us to tailor and optimize each development project from the start. The more we know about your substance and targets, the better we can design the project for positive, repeatable findings.

Explore which vaccine platforms our projects focus on

Your guide to ambient drying

For many formulation scientists, ambient drying is an unfamiliar technology. It can involve different kinds of excipients to those used in spray drying or freeze drying for example. With our advanced expertise in ambient drying our project team guides partners on how to get the best results out of LaminarPace drying for their molecules and compounds.

Learn more about ambient drying